The first quarter saw a rash of approvals. Among the most noteworthy small molecules are the first new drug for Parkinson's disease in a decade and a compound specific for STAT/JAK 1 and 2 in rheumatoid arthritis. Whereas the EMA approved the arthritis drug, the FDA is asking the company for more trial data. First-in class monoclonals were registered that target B-cell epitope CD20 for primary progressive multiple sclerosis, interleukin (IL)-4 receptor for advanced eczema and IL-17 receptor for psoriasis. Positive trial results were also announced for Kite Pharma's chimeric antigen receptor (CAR)-T cell therapy against CD19 in lymphoma.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: 1Q17. Nat Biotechnol 35, 400 (2017). https://doi.org/10.1038/nbt.3874
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3874
